Ranbaxy stock spurts over 5% in early trade

Image
Press Trust of India Mumbai
Last Updated : Jan 20 2013 | 9:33 PM IST

Shares of Ranbaxy Laboratories jumped by over 5% in morning trade on the bourses today after the company posted a better-than-expected profit of Rs 304.4 crore for the first quarter ended March 31, 2011.

The scrip of the country's biggest drug-maker rose by 5.37% to touch an early high of Rs 473.25 on the Bombay Stock Exchange (BSE).

In a similar fashion, the stock zoomed up by 5% to touch a high of Rs 472.90 on the National Stock Exchange.

On the volume front, over 26 lakh shares of the company were traded on the two bourses within the first few minutes of trade.

"The results have matched the streets expectations, which are definitely better-than-expected, that is why the stock is seeing buying interest by the investors," Ashika Stock Brokers Research Head Paras Bothra said.

The drug major yesterday posted a consolidated profit after tax (PAT) of Rs 304.4 crore for the first quarter ended March 31, 2011.

The company's PAT for the quarter is significantly lower than the Rs 960.6 crore that it had posted in the same period previous year.

However, the figures were not comparable as it had witnessed a significant jump in sales in the same period last year through the launch of antiviral, Valacyclovir with 180 days of exclusive marketing rights in the US in the last quarter of 2009.

The results were announced after the market close yesterday.

Meanwhile, the BSE benchmark Sensex was trading flat at 18,521.50 at 1048 hours.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 11 2011 | 11:42 AM IST

Next Story